US picks five drugmakers for ‘warp speed’ push for virus vaccine

Alejandro Arrieche
Last Updated: June 4, 2020
stephane bancel ceo moderna warp speed

The US government has picked five firms currently developing a coronavirus vaccine as part of its operation ‘Warp Speed’, to find a fast treatment for the disease.

Operation Warp Speed seeks to compress a vaccine process that is typically years long into a matter of months, in part by spending as much as $10bn on research, manufacturing and agreements to guarantee purchase of the vaccines.

The five companies include US-based biotech Moderna (MRNA), pharma giants AstraZeneca, Pfizer, and Merck, and health care conglomerate Johnson & Johnson.

The program aims to assist at least three out of the five companies in conducting large-scale randomized clinical trials to ensure the safeness and effectiveness of their vaccines, while it also seeks to assist them in the development of suitable treatments and diagnostics for the disease.

US President Donald Trump on Tuesday tweeted: “Vaccines are coming along really well. Moving faster than anticipated. Good news ahead (in many ways)!”.

From these five candidates, Moderna appears to be the company that has moved faster towards the development of a potential vaccine, as the biotech’s mRNA-1273 candidate has already moved on to Phase 2, which involves testing the drug in a group of 600 patients, after a successful Phase 1 that managed to produce antibodies to neutralize the virus.

Shares of US biotech firm Moderna (MRNA) have skyrocketed during the year, after the company emerged as the front-runner in the race towards finding a vaccine for the virus causing the world’s latest pandemic.

The stock accumulates a gain of 188% since January, a performance that overshadows its four rivals in Operation Warp Speed, with AstraZeneca (AZN), Johnson & Johnson, Merck, Pfizer posting 52%, 17%, 7% and -9% gains respectively. Moderna ended up yesterday’s stock trading session at $59.89 and its up 1.4% during pre-market trading.

Moderna performance stock chart ytd 2020

Even though the shares of Moderna led by chief eccutive Stéphane Bancel (pictured), have rallied recently, analysts are still bullish on it as reflected by the stock’s $84 12-month price target, which represents a 40% upside based on yesterday’s price.

Meanwhile, Merck’s chief executive Ken Frazier recently commented about the aggressiveness of vaccine development time frames, saying that very large clinical trials often take years to complete.

The pharma boss added: “Speed is one factor, but in some ways we don’t really accept the concept of a race … We understand the urgency, but our goal isn’t to be the frontrunner in the early stages — it’s to develop a vaccine that is safe and effective”.

Open a Stocks Account and Get $5 Free

  • Platform
  • Features
  • Rating
  • Visit Site
  • Sign up now and claim a $5 reward
  • Low minimum investment starting at $5
  • No minimum deposit to open an account
  • Fractional shares are available



    https://learnbonds.com/visit/StashCreate your account
    Hide Reviews
    All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
    Alejandro Arrieche

    Alejandro is a financial writer with 7 years of experience in financial management and financial analysis. He writes technical content about economics, finance, investments, and real estate and have also assisted financial businesses in building their digital marketing strategy. His favorite topics are value investing and financial analysis.


    Leading Social Trading Platform with 0% Commission

    Leading Social Trading Platform with 0% Commission

    Leading Social Trading Platform with 0% Commission


    75% of investors lose money when trading CFDs.

    Leading Social Trading Platform with 0% Commission

    75% of investors lose money when trading CFDs.

    HTML Snippets Powered By : XYZScripts.com